| Company Name: | Vanda Pharmaceuticals Inc | | | Ticker Symbol: | VNDA | | CIK Number: | 0001347178 | | WWW Address: | http://www.vandapharma.com |
| CEO: | Dr. Mihael Hristos Polymeropoulos,M.D. | | No. of Employees: | 142 |
| Common Issue Type: | CS | | Business Description: | Vanda Pharmaceuticals Inc. is a biopharmaceutical Company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 14.91 |  0.0 | 14.02 | 17.5 | | 16.15 | 15.27 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 789.7 | 53.0 | 0.00 | 0.50 | 0.00 | 32.4 | 0.0 | 33.44 - 13.67 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 15.29 | $ | | PE Ratio - LTM | 32.4 | |
| Market Capitalisation | 789.7 | mil |
| Latest Shares Outstanding | 53.0 | mil |
| Earnings pS (EPS) | 0.50 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 715,252 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 42.8 | mil |
| Float as % of Shares Outstanding | 0.8 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.20 | % |
| Gross Profit Margin | 89.4 | % |
| EBITDA Margin | 12.8 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 71.9 | % |
| Return on Assets (ROA) | 9.4 | % |
| Return on Equity (ROE) | 12.4 | % |
| Return on Capital Invested (ROCI) | 12.4 | % |
| Current Ratio | 5.6 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | | |
| Total Debt/Equity (Gearing Ratio) | | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 4.65 | $ |
| Cash pS | 0.00 | $ |
| Book-Value pS | 5.26 | $ |
| Tangible Book-Value pS | 4.74 | $ |
| Cash Flow pS | 0.70 | $ |
| Free Cash Flow pS | 0.23 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.91 | |
| Price/Tangible Book Ratio | 0.00 | |
| Price/Cash Flow | 21.8 | |
| Price/Free Cash Flow | 67.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -2.8 | | 575,000 | |
| 4 Weeks | 17.41 | 13.67 | 16.65 | -8.2 | | 623,953 | 12,479,063 |
| 13 Weeks | 21.41 | 13.67 | 20.14 | -24.1 | | 666,253 | 41,973,994 |
| 26 Weeks | 33.44 | 13.67 | 23.60 | -35.2 | | 777,163 | 95,591,165 |
| 52 Weeks | 33.44 | 13.67 | 16.55 | -7.6 | | 726,582 | 181,645,585 |
| YTD | 31.39 | 13.67 | - | -43.4 | | 783,375 | 74,420,681 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 15.82 | 16.04 | 17.38 | 21.77 | 21.55 | 0.00 | 0.00 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.42 | 0.5 | 0.21 |
| Income | | 0.0 | |
| Dividend | | 0.0 | |
| Capital Spending | | NA | 0.34 |
| R&D | 5.32 | NA | 50.96 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -0.9 | -0.9 | 4.7 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.13 | 0.13 | -0.63 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 74.10 |
| Current Ratio | 5.6 |
| Quick Ratio (Acid Test) | 5.4 |
| Liquidity Ratio (Cash) | 6.01 |
| Receivables Turnover | 8.3 |
| Average Collection Period | 43 |
| Working Capital/Equity | 89.4 |
| Working Capital pS | 4.68 |
| Cash-Flow pS | 0.57 |
| Free Cash-Flow pS | 0.09 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 1.81 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 0.0 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.0 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.00 |
| Tobin's Q Ratio | 2.44 |
| Current P/E Ratio - LTM | 32.40 |
| Enterprise Value (EV)/EBITDA | 19.90 |
| Enterprise Value (EV)/Free Cash Flow | 148.24 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 0.00 |
| Price/Book Ratio - LTM | 2.91 |
| Price/Cash Flow Ratio | 21.8 |
| Price/Free Cash Flow Ratio - LTM | 67.1 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 81.6 |
| 5-Y Low P/E Ratio | 16.9 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | -24 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.04 |
| Tangible Book Value pS - LTM | 4.74 |
| Book Value pS - LTM | 5.26 |
| Capital Invested pS | 5.20 |
| Cash pS - LTM | 0.00 |
| Cash Flow pS - LTM | 0.70 |
| Free Cash Flow pS - LTM | 0.23 |
| Earnings pS (EPS) | 0.50 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 2.39 |
| Free Cash Flow Margin 5YEAR AVG | -35.48 |
| Net Profit Margin | 0.1 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.70 |
| Return on Equity (ROE) | 0.1 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.70 |
| Return on Capital Invested (ROCI) | 0.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.0 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | 0.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.0 |
| Gross Profit Margin | 89.4 |
| Gross Profit Margin - 5YEAR AVRG. | 0.9 |
| EBITDA Margin - LTM | 12.8 |
| EBIT Margin - LTM | 11.3 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | |
| Revenue per Employee | 715,252 |
| Net Income per Employee | 93,363 |
| Average Collection Period | |
| Receivables Turnover | 8.3 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 22.4 |
| Inventory/Sales | 0.5 |
| Accounts Payble/Sales | 2.68 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | 0.78 |
| Fixed Assets Turnover | 5.85 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 3.17 |
| Revenue per $ Plant | 43.72 |
| Revenue per $ Common Equity | 0.70 |
| Revenue per $ Capital Invested | 0.70 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 54.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1.0 |
| Research & Devlopment (R&D) as % of Revenue | 22.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 22.6 |
|
|  
|
| |
 |  |
